Abstract

Simple SummaryAlthough immune checkpoint inhibitors have a potential role in thyroid-related complications, no study has investigated factors associated with such adverse events. This study aims to explore the factors associated with thyroid-related adverse events in patients with anti-PD-1/PD-L1 agents by training predictive models utilizing various machine learning approaches. The results of this study could be used to develop individually tailored intervention strategies to prevent immune checkpoint inhibitor-induced thyroid-related outcomes.Targets of immune checkpoint inhibitors (ICIs) regulate immune homeostasis and prevent autoimmunity by downregulating immune responses and by inhibiting T cell activation. Although ICIs are widely used in immunotherapy because of their good clinical efficacy, they can also induce autoimmune-related adverse events. Thyroid-related adverse events are frequently associated with anti-programmed cell death 1 (PD-1) or anti-programmed cell death-ligand 1 (PD-L1) agents. The present study aims to investigate the factors associated with thyroid dysfunction in patients receiving PD-1 or PD-L1 inhibitors and to develop various machine learning approaches to predict complications. A total of 187 patients were enrolled in this study. Logistic regression analysis was conducted to investigate the association between such factors and adverse events. Various machine learning methods were used to predict thyroid-related complications. After adjusting for covariates, we found that smoking history and hypertension increase the risk of thyroid dysfunction by approximately 3.7 and 4.1 times, respectively (95% confidence intervals (CIs) 1.338–10.496 and 1.478–11.332, p = 0.012 and 0.007). In contrast, patients taking opioids showed an approximately 4.0-fold lower risk of thyroid-related complications than those not taking them (95% CI 1.464–11.111, p = 0.007). Among the machine learning models, random forest showed the best prediction, with an area under the receiver operating characteristic of 0.770 (95% CI 0.648–0.883) and an area under the precision-recall of 0.510 (95%CI 0.357–0.666). Hence, this study utilized various machine learning models for prediction and showed that factors such as smoking history, hypertension, and opioids are associated with thyroid-related adverse events in cancer patients receiving PD-1/PD-L1 inhibitors.

Highlights

  • Cancer has become a global health problem and a leading cause of death worldwide.In 2020, there were approximately 19.3 million new cancer cases and 10 million cancer deaths globally

  • This study explores the factors associated with the development of thyroid-related adverse events in patients administered anti-PD-1/programmed cell death-ligand 1 (PD-L1) agents using training predictive models through various machine learning approaches

  • Data on 187 patients who received immune checkpoint inhibitors (ICIs) were used for the analysis

Read more

Summary

Introduction

Cancer has become a global health problem and a leading cause of death worldwide. In 2020, there were approximately 19.3 million new cancer cases and 10 million cancer deaths globally. The top three cancer types in terms of the estimated number of patients are breast, lung, and prostate cancers. Lung cancer is the leading cause of cancer death [1]. The identification of molecular mechanisms through which cancer develops and metastasizes is actively pursued; in particular, T lymphocytes, especially for antigendirected cytotoxicity, have attracted increasing interest in developing immunotherapy for cancer treatment [2]. Various negative regulators of T cell activation act as checkpoint molecules, such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitors, antiprogrammed cell death 1 (PD-1) agents, and anti-programmed cell death-ligand 1 (PDL1) agents

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.